glp-1 egfr cut off receptor agonists in patients with chronic kidney disease and either overweight or obesity Diabetes Medications Dose Adjustment for

Diabetes 71 , 18521861 (2022)

GLP-1 weight-loss drugs are cutting calories and grocery bills, according to a new study from Cornells SC Johnson College of Business using data from Numerator

Acute kidney injury in diabetes mellitus

Non-prescription and compounded peptides such as BPC-157, CJC-1295/Ipamorelin, AOD-9604, and MOTS-c are not FDA-approved for weight loss and lack the same regulatory oversight and clinical safety data as the GLP-1 drugs in the table above, which is why they should only be used under the guidance of a licensed medical provider who can order lab work, personalize dosing, and monitor for side effects throughout treatment